Mark Sulkowski

Mark Sulkowski, MD, is a Professor of Medicine and serves as the Medical Director of the Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology in the Department of Medicine at the Johns Hopkins University School of Medicine in Baltimore, Maryland. He also serves as the Associate Dean for Research in the Capital Region (CAPRES) for Johns Hopkins Medicine. He received his MD from Temple University School of Medicine, Philadelphia, PA (1992), pursued training in Internal Medicine at Duke University School of Medicine, Durham, NC (1995) and completed his Fellowship in Infectious Diseases (1998) at the Johns Hopkins University School of Medicine.

Prof. Sulkowski has been the principal investigator for more than 100 clinical trials related to the management of viral hepatitis in persons with and without HIV co-infection and has been selected as the global principal investigator on more than a dozen such studies, including the largest clinical trial of agents for the treatment of hepatitis C (New England Journal of Medicine, 2009) and the vanguard study of combination therapy with direct inhibitors of the HCV NS5A and NS5B non-structural proteins (New England Journal of Medicine, 2014). He is the Chair of the Hepatitis Transformative Sciences Group of the National Institutes of Health-funded adult AIDS Clinical Trials Group (ACTG) leading translational studies of liver disease in persons with HIV infection, namely hepatitis B, hepatitis C, and fatty liver disease. He is an elected member of the American Society for Clinical Investigation (ASCI, 2011) and the American Association of Physicians (AAP, 2017).

Prof. Sulkowski is a member of numerous professional societies including the American Association for the Study of Liver Diseases (AASLD), the European Association for the Study of the Liver (EASL), and the Infectious Diseases Society of America (IDSA). He is widely published with works in Annals of Internal Medicine, New England Journal of Medicine, JAMA, Journal of Infectious Diseases, Journal of Hepatology, and Hepatology. In 2017 and 2018, he was named as a Highly Cited Researcher (Clarivate Analytics) defined as the being in the top 1% of global researchers in 21 fields of the sciences and social sciences based on the number of citations for papers. As an invited lecturer, he has been frequently invited to present at major national and international medical congresses and has educated learners in more than 25 countries.